Alliance Pharma plc (LON:APH) had its price target decreased by research analysts at FinnCap from GBX 65 ($0.85) to GBX 58 ($0.76) in a report released on Monday, July 31st. The firm presently has a “buy” rating on the stock. FinnCap’s price objective would suggest a potential upside of 12.08% from the stock’s previous close.
Separately, Numis Securities Ltd restated a “buy” rating and set a GBX 60 ($0.78) target price on shares of Alliance Pharma plc in a report on Tuesday, July 18th.
Shares of Alliance Pharma plc (APH) opened at 51.75 on Monday. The firm has a 50-day moving average of GBX 52.37 and a 200 day moving average of GBX 50.02. The firm’s market capitalization is GBX 244.63 million. Alliance Pharma plc has a 12-month low of GBX 41.33 and a 12-month high of GBX 57.50.
About Alliance Pharma plc
Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.
Receive News & Ratings for Alliance Pharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma plc and related companies with MarketBeat.com's FREE daily email newsletter.
